Andersson Karl-Erik, Hedlund Petter
Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden.
Urology. 2002 Nov;60(5 Suppl 1):13-20; discussion 20-1. doi: 10.1016/s0090-4295(02)01786-7.
Myogenic activity, distention of the detrusor, and signals from the urothelium may initiate voiding. In the bladder, afferent nerves have been identified not only in the detrusor, but also suburothelially, where they form a plexus that lies immediately beneath the epithelial lining. Extracellular adenosine triphosphate (ATP) has been found to mediate excitation of small-diameter sensory neurons via P2X3 receptors, and it has been shown that bladder distention causes release of ATP from the urothelium. In turn, ATP can activate P2X3 receptors on suburothelial afferent nerve terminals to evoke a neural discharge. However, most probably, not only ATP but also a cascade of inhibitory and stimulatory transmitters and mediators are involved in the transduction mechanisms underlying the activation of afferent fibers during bladder filling. These mechanisms may be targets for future drugs. The central nervous control of micturition involves many transmitter systems, which may be suitable targets for pharmacologic intervention. gamma-Aminobutyric acid, dopamine, enkephalin, serotonin, and noradrenaline receptors and mechanisms are known to influence micturition, and potentially, drugs that affect these systems could be developed for clinical use. However, a selective action on the lower urinary tract may be difficult to obtain. Most drugs currently used for treatment of detrusor overactivity have a peripheral site of action, mainly the efferent (cholinergic) neurotransmission and/or the detrusor muscle itself. In the normal bladder, muscarinic receptor stimulation produces the main part of detrusor contraction, but evidence is accumulating that in disease states, such as neurogenic bladders, outflow obstruction, idiopathic detrusor instability, and interstitial cystitis, as well as in the aging bladder, a noncholinergic activation via purinergic receptors may occur. If this component of activation is responsible not only for part of the bladder contractions, but also for the symptoms of the overactive bladder, it should be considered an important target for therapeutic interventions.
肌源性活动、逼尿肌扩张以及来自尿路上皮的信号可能引发排尿。在膀胱中,不仅在逼尿肌中发现了传入神经,在尿路上皮下层也有,它们在那里形成一个紧邻上皮衬里的神经丛。已发现细胞外三磷酸腺苷(ATP)通过P2X3受体介导小直径感觉神经元的兴奋,并且已表明膀胱扩张会导致尿路上皮释放ATP。反过来,ATP可激活尿路上皮下传入神经末梢上的P2X3受体以引发神经放电。然而,很可能不仅ATP,而且一系列抑制性和刺激性递质及介质都参与膀胱充盈期间传入纤维激活的转导机制。这些机制可能是未来药物的作用靶点。排尿的中枢神经控制涉及许多递质系统,它们可能是药物干预的合适靶点。已知γ-氨基丁酸、多巴胺、脑啡肽、5-羟色胺和去甲肾上腺素受体及机制会影响排尿,并且潜在地,可开发影响这些系统的药物用于临床。然而,可能难以获得对下尿路的选择性作用。目前用于治疗逼尿肌过度活动的大多数药物作用于外周部位,主要是传出(胆碱能)神经传递和/或逼尿肌本身。在正常膀胱中,毒蕈碱受体刺激产生逼尿肌收缩的主要部分,但越来越多的证据表明,在疾病状态下,如神经源性膀胱、流出道梗阻、特发性逼尿肌不稳定和间质性膀胱炎,以及在老化的膀胱中,可能会通过嘌呤能受体发生非胆碱能激活。如果这种激活成分不仅负责部分膀胱收缩,还负责膀胱过度活动的症状,那么它应被视为治疗干预的重要靶点。